Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG)

传染病临床研究联盟领导小组 (IDCRCLG)

• 批准号: 10462061
• 负责人: Kathleen Neuzil
• 金额: $ 37.91万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-07-27 至 2023-05-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10462061
• 关键词: Address; Adopted; Ancillary Study; Area; Biological Assay; Biological Products; Clinical; Clinical Research; Clinical Trials; Collaborations; Common Data Element; Communicable Diseases; Communication; Communities; Complex; Containment; Data; Data Science; Diagnosis; Diagnostic Equipment; Diarrhea; Dissemination and Implementation; Drug Kinetics; Ebola; Elements; Emerging Communicable Diseases; Ensure; Environment; Epidemic; Ethics; Evaluation; Foundations; Funding; Future; Genomics; Human; Immunologics; Immunology; Infection; Influentials; Infrastructure; Institution; International; Intervention Trial; Investigational New Drug Application; Laboratories; Laboratory Research; Leadership; Link; Longevity; Malaria; Mentors; Methods; Monitor; National Institute of Allergy and Infectious Disease; Outcome; Participant; Pathogenesis; Patients; Performance; Phase; Policies; Population; Population Heterogeneity; Prevention; Private Sector; Procedures; Proteomics; Protocols documentation; Public Health; Publications; Research; Research Activity; Research Design; Research Priority; Resources; Respiratory Tract Infections; Risk Assessment; Science; Scientist; Services; Sexually Transmitted Diseases; Site; Specimen; Systems Biology; Techniques; Therapeutic; Time; Training; Translating; Tropical Disease; Underserved Population; United States; United States National Institutes of Health; Universities; Vaccines; Vulnerable Populations; ZIKA; career development; clinical application; data management; drug discovery; enteric infection; experience; first-in-human; flexibility; global health; improved; industry partner; infectious disease treatment; influenza pneumonia; innovation; laboratory experiment; lipidomics; metabolomics; microbial; microbiome; multi-site trial; next generation; novel; novel strategies; operation; organizational structure; performance site; product development; programs; protocol development; public health emergency; public-private partnership; reconstitution; research study; risk mitigation; support network; transcriptomics; trial design; vaccine evaluation; vaccine trial; working group

This Infectious Diseases Clinical Research Consortium Leadership Group (IDCRCLG or LG) is a new, collaborative national partnership of leading infectious diseases, human immunology and clinical research experts from eight outstanding academic institutions providing experience, guidance, global connectivity and innovative approaches to address NIH/NIAID clinical research priorities. The emphasis (and strength) of the IDCRCLG is to facilitate, plan and help implement clinical research for respiratory and enteric infections, malaria/tropical diseases, and sexually transmitted infections (STIs), and to respond to emerging infectious diseases (EID). Priority research will include interventional trials and clinical research studies for vaccines, biologics, therapeutics, diagnostics and devices targeting these infectious diseases. The LG’s experts and their programs at the eight universities and beyond have a historic record of accomplishment in vaccine and therapeutic clinical research, and immunologic and pathogenesis studies for these NIAID-priority infectious diseases. The LG brings extensive expertise with the conduct of Phase I-IV clinical trials including first- in-human studies, cutting-edge human immunology, pharmacokinetics; engagement with diverse populations both nationally/internationally, sIRBs, innovative public-private partnerships, and Investigational New Drug applications (INDs). The group also has strong connectivity to and will leverage NIH/NIAID-supported networks; extensive experience in collaborating with industry partners and foundations, and leadership of complex administrative consortia. This cadre of diverse infectious diseases experts proposes to establish and operate with NIAID and the reconstituted Vaccine and Treatment Evaluation Units (VTEUs), an integrated, highly- functional, efficient IDCRC to develop innovative scientific and operational strategies in priorities such as vaccines and STI clinical research. The organizational structure supporting the science and operations of the IDCRCLG is composed of a Leadership Operations Center including Expert Working Groups, a Clinical Operations Unit, a Laboratory Operations Unit, and a Statistical and Data Science Unit. Key functions of the LG are to propose, review and prioritize innovative concepts; to enhance integration and efficiency in operations; to form collaborative teams; to ensure quality and timely protocol implementation; to disseminate the results; to promote integration of all populations in IDCRC research across the human lifespan; and to attract, engage and retain the next generation of scientists in infectious diseases clinical research. In addition, the LG’s experience with EID threats, links to global partners/sites, access to the highest-level clinical and laboratory containment facilities and to large populations will help the IDCRC to respond rapidly (surge capacity) during a public health emergency. The LG’s decades of experience with public health, regulatory agencies, product development pipelines further enhance this capacity. The IDCRCLG and the institutions they represent are committed through dedicated PI/leadership effort, space, infrastructure and direct funds to develop the IDCRC.

该传染病临床研究联盟领导小组（IDCRCLG 或 LG）是一个新的、 主要传染病、人类免疫学和临床研究的国家合作伙伴关系 来自八个杰出学术机构的专家提供经验、指导、全球联系和 解决 NIH/NIAID 临床研究优先事项的创新方法。的重点（和强度） IDCRCLG 旨在促进、规划和帮助实施呼吸道和肠道感染的临床研究， 疟疾/热带病和性传播感染（STI），并应对新出现的 传染病（EID）。优先研究将包括介入试验和临床研究 针对这些传染病的疫苗、生物制品、治疗方法、诊断方法和设备。 LG的 八所大学及其他大学的专家及其项目在以下方面取得了历史性的成就： NIAID 优先的疫苗和治疗临床研究，以及免疫学和发病机制研究 传染病。 LG 带来了开展 I-IV 期临床试验的丰富专业知识，包括首次- 人体研究、尖端人类免疫学、药代动力学；与不同人群的接触 国内/国际、sIRB、创新的公私伙伴关系和研究性新药 申请（IND）。该小组还与 NIH/NIAID 支持的网络建立了强大的连接，并将利用该网络； 与行业合作伙伴和基金会合作的丰富经验，以及复杂的领导力 行政财团。这支由不同传染病专家组成的骨干队伍提议建立和运作 与 NIAID 和重建的疫苗和治疗评估单位 (VTEU) 一起，一个综合的、高度 功能齐全、高效的 IDCRC 在优先事项中制定创新的科学和运营战略，例如 疫苗和性传播感染临床研究。支持科学和运营的组织结构 IDCRCLG 由领导运营中心（包括专家工作组）、临床 运营部门、实验室运营部门以及统计和数据科学部门。主要功能 LG 将提出、审查和优先考虑创新概念；加强整合和效率 运营;组建协作团队；确保协议的质量和及时实施；传播 结果;促进所有人群在整个人类生命周期中融入 IDCRC 研究；并吸引， 吸引并留住下一代科学家从事传染病临床研究。此外，LG 的 应对 EID 威胁的经验、与全球合作伙伴/站点的链接、访问最高水平的临床和实验室的机会 收容设施和大量人口将有助于 IDCRC 在疫情期间快速做出反应（增援能力） 突发公共卫生事件。 LG 在公共卫生、监管机构、产品方面拥有数十年的经验 开发管道进一步增强了这种能力。 IDCRCLG 及其代表的机构是 致力于通过专门的 PI/领导力努力、空间、基础设施和直接资金来发展 IDCRC。